DK1976880T3 - Pharmaceutical compositions with resistance to soluble cea - Google Patents

Pharmaceutical compositions with resistance to soluble cea Download PDF

Info

Publication number
DK1976880T3
DK1976880T3 DK06841112.3T DK06841112T DK1976880T3 DK 1976880 T3 DK1976880 T3 DK 1976880T3 DK 06841112 T DK06841112 T DK 06841112T DK 1976880 T3 DK1976880 T3 DK 1976880T3
Authority
DK
Denmark
Prior art keywords
ser
gly
seq
thr
cea
Prior art date
Application number
DK06841112.3T
Other languages
Danish (da)
English (en)
Inventor
Ralf LUTTERBÜSE
Petra Mayer
Evelyne Schaller
Doris Rau
Susanne Mangold
Peter Kufer
Alexander Murr
Monika Wissinger
Tobias Raum
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Application granted granted Critical
Publication of DK1976880T3 publication Critical patent/DK1976880T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK06841112.3T 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea DK1976880T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75196305P 2005-12-21 2005-12-21
EP05028064 2005-12-21
US78086106P 2006-03-10 2006-03-10
PCT/EP2006/012425 WO2007071426A1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea

Publications (1)

Publication Number Publication Date
DK1976880T3 true DK1976880T3 (en) 2016-09-26

Family

ID=40413962

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06841112.3T DK1976880T3 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea

Country Status (24)

Country Link
US (3) US8394926B2 (enExample)
EP (2) EP1976880B1 (enExample)
JP (2) JP5399712B2 (enExample)
KR (1) KR101287777B1 (enExample)
CN (1) CN101370827B (enExample)
AU (1) AU2006328886C1 (enExample)
BR (1) BRPI0620632A2 (enExample)
CA (1) CA2633766C (enExample)
CY (1) CY1118053T1 (enExample)
DK (1) DK1976880T3 (enExample)
ES (1) ES2595091T3 (enExample)
HR (1) HRP20161216T1 (enExample)
HU (1) HUE031151T2 (enExample)
IL (1) IL192277A (enExample)
LT (1) LT1976880T (enExample)
ME (1) ME02581B (enExample)
NZ (1) NZ569204A (enExample)
PL (1) PL1976880T3 (enExample)
PT (1) PT1976880T (enExample)
RS (1) RS55181B1 (enExample)
RU (2) RU2426743C2 (enExample)
SG (1) SG193141A1 (enExample)
WO (1) WO2007071426A1 (enExample)
ZA (1) ZA200805400B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
AU2006328882B2 (en) * 2005-12-21 2011-06-16 Amgen Research (Munich) Gmbh Pharmaceutical antibody compositions with resistance to soluble CEA
LT1976880T (lt) * 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2782330A1 (en) * 2009-12-01 2011-06-09 Medimmune, Llc Improved methods and compositions for detecting and treating cea-expressing cancers
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR102643443B1 (ko) 2012-11-13 2024-03-06 비온테크 에스이 클라우딘 발현 암 질환의 치료제
KR102661801B1 (ko) 2012-11-20 2024-04-26 사노피 항-ceacam5 항체 및 이의 용도
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
PE20151410A1 (es) * 2013-02-26 2015-09-18 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
AR095596A1 (es) 2013-03-15 2015-10-28 Amgen Res Munich Gmbh Moléculas de unión de cadena única comprendiendo n-terminal abp
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
MD20160130A2 (ro) 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Anticorpi umanizaţi contra CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
MX376225B (es) 2015-02-24 2025-03-07 Bioatla Llc Proteínas biológicas condicionalmente activas
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43025A (fr) 2015-10-02 2021-05-26 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
PL3387015T3 (pl) 2015-12-09 2022-02-14 F. Hoffmann-La Roche Ag Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
MX2018008347A (es) 2016-01-08 2018-12-06 Hoffmann La Roche Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
PL3464380T3 (pl) 2016-06-02 2025-03-31 Immunocore Limited Schemat dawkowania białka fuzyjnego specyficznego dla gp100 tcr - scfv anty-cd3
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
CN110087682B (zh) 2016-12-19 2023-12-15 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
CA3047070A1 (en) 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
CN107058234B (zh) * 2017-05-12 2019-09-13 常州市第一人民医院 Car.il-33-t及其制备与应用
ES3023158T3 (en) 2017-08-01 2025-05-30 Ab Therapeutics Inc Bispecific antibodies and uses thereof
TW201930353A (zh) 2017-11-01 2019-08-01 瑞士商赫孚孟拉羅股份公司 使用經靶向之ox40促效劑的組合療法
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
AU2019281358A1 (en) 2018-06-03 2021-01-07 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
CN112424228B (zh) 2018-07-04 2024-08-09 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
CA3123493A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
SG11202107843WA (en) 2019-02-07 2021-08-30 Sanofi Sa Use of anti-ceacam5 immunoconjugates for treating lung cancer
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CA3142887A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
JP7354306B2 (ja) * 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
EP4025254A1 (en) 2019-09-03 2022-07-13 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
CA3150265A1 (en) 2019-09-18 2021-03-25 Sara MAJOCCHI BISPECIFIC ANTIBODIES DIRECTED AGAINST CEACAM5 AND CD3
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
JP7709431B2 (ja) 2019-10-25 2025-07-16 ボルト バイオセラピューティクス、インコーポレーテッド チエノアゼピン、イムノコンジュゲート、及びそれらの使用
TW202128765A (zh) * 2019-11-21 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種雙特異性抗體
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
AU2021326516A1 (en) 2020-08-13 2023-04-13 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
EP4259210A2 (en) 2020-12-11 2023-10-18 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
MX2023007220A (es) 2020-12-18 2023-08-25 Lamkap Bio Beta Ltd Anticuerpos biespecificos contra el antigeno carcinoembrionario humano (ceacam5) y el cumulo de diferenciacion 47 (cd47).
EP4313162A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
AU2022245340A1 (en) 2021-03-26 2023-11-09 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
CN119233830A (zh) 2022-03-23 2024-12-31 新锐生物技术公司 用于靶向表达癌胚抗原的肿瘤的抗体缀合物
IL316117A (en) 2022-06-16 2024-12-01 Lamkap Bio Beta Ltd Combination drug regimen of anti-CEACAM5 and CD47 antigens and bispecific anti-CEACAM5 and CD3 antigens
AU2024237581A1 (en) 2023-03-14 2025-10-02 Xencor, Inc. Anti-cd28 compositions
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
BR9107206A (pt) 1990-12-05 1993-11-03 Novo Nordisk As Processo para produzir uma variante de proteina que evoca uma resposta imunogenica diminuida em animais,produtos obtidos,composicao e uso
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
PL199747B1 (pl) 1998-04-21 2008-10-31 Micromet Ag Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
KR20040074587A (ko) 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7820166B2 (en) * 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
AU2006328882B2 (en) * 2005-12-21 2011-06-16 Amgen Research (Munich) Gmbh Pharmaceutical antibody compositions with resistance to soluble CEA
LT1976880T (lt) 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea

Also Published As

Publication number Publication date
RS55181B1 (sr) 2017-01-31
JP2009520734A (ja) 2009-05-28
SG193141A1 (en) 2013-09-30
RU2573893C2 (ru) 2016-01-27
ES2595091T3 (es) 2016-12-27
US20170137538A1 (en) 2017-05-18
CN101370827B (zh) 2015-10-14
LT1976880T (lt) 2016-10-10
BRPI0620632A2 (pt) 2011-12-20
PL1976880T3 (pl) 2017-01-31
IL192277A (en) 2016-08-31
US20130273050A1 (en) 2013-10-17
NZ569204A (en) 2012-03-30
HRP20161216T1 (hr) 2016-11-18
ZA200805400B (en) 2009-09-30
PT1976880T (pt) 2016-09-28
RU2008129787A (ru) 2010-01-27
RU2010148652A (ru) 2012-06-10
JP2013056885A (ja) 2013-03-28
CA2633766C (en) 2016-06-28
HUE031151T2 (en) 2017-06-28
CN101370827A (zh) 2009-02-18
RU2426743C2 (ru) 2011-08-20
AU2006328886C1 (en) 2011-11-17
KR101287777B1 (ko) 2013-07-23
EP1976880B1 (en) 2016-07-06
ME02581B (me) 2017-06-20
US20090226432A1 (en) 2009-09-10
KR20080079330A (ko) 2008-08-29
AU2006328886B2 (en) 2011-04-14
CA2633766A1 (en) 2007-06-28
US9695250B2 (en) 2017-07-04
WO2007071426A1 (en) 2007-06-28
IL192277A0 (en) 2008-12-29
EP1976880A1 (en) 2008-10-08
JP5399712B2 (ja) 2014-01-29
EP2527370A1 (en) 2012-11-28
US9982063B2 (en) 2018-05-29
CY1118053T1 (el) 2017-06-28
US8394926B2 (en) 2013-03-12
AU2006328886A1 (en) 2007-06-28
HK1115890A1 (zh) 2008-12-12

Similar Documents

Publication Publication Date Title
DK1976880T3 (en) Pharmaceutical compositions with resistance to soluble cea
US8901278B2 (en) Pharmaceutical antibody compositions with resistance to soluble CEA
KR101671039B1 (ko) 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도
JP2022516505A (ja) 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
KR20210031913A (ko) 항-인간 pd-l1 항체 및 그것의 용도
AU2011204778B2 (en) Pharmaceutical compositions with resistance to soluble CEA
HK1115890B (en) Pharmaceutical compositions with resistance to soluble cea
HK1178548A (en) Compounds having resistance to soluble cea
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
NZ569144A (en) Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA